Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Despite significant efficacy, one of the major limitations of small-molecule Bruton's tyrosine
kinase (BTK) agents is the presence of clinically acquired resistance, which remains a major …

Ibrutinib (IBR) is an oral covalent inhibitor of Bruton's tyrosine kinase (BTK) that has been
approved for the treatment of hematological malignancies. It was reported that IBR exhibited …

Bruton's Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both
physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became …

Bruton's tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the
development, maturation, and signaling of B cells. BTK has been found to regulate cell …

Purpose: Epithelial and endothelial tyrosine kinase (Etk), also known as bone marrow X
kinase (Bmx), was found to be critical in modulating the chemoresistance of small-cell lung …

Simple Summary Prostate cancer progression is mainly driven by the androgen receptor
(AR) signaling pathway and its inhibition has been the cornerstone in the treatment of …

Background Multiple mechanisms of immunosuppression have been identified in the tumor
microenvironment including regulatory B cells (B reg). Recently, we have shown that B reg …

Standard interventions for glioma include surgery, radiation and chemotherapies but the
prognosis for malignant cases such as glioblastoma multiforme remain grim. Even with …

Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase that has mainly been
studied in haematopoietic cells. We have investigated whether BTK is a potential therapeutic …